Shire under a £1bn shadow

Malcolm Withers12 April 2012

FEARS about competition and cost pressures sent Shire Pharmaceuticals' shares plunging to a two-year low, a 32% setback that wiped more than £1bn from its market value.

US-owned Barr Laboratories has produced its own version of Adderall, which was specially developed by Shire for children suffering from hyperactivity, and there are worries about Barr's products gaining market share.

Shire has countered the Barr move by producing a one-shot-a-day version of Adderall, which is Shire's lead drug, contributing a third of revenues.

Although Shire has launched three other drugs, the process of researching and trialling other drugs could mean extra expenditure in the short term.

However, chief executive Rolf Stahel said that in the medium- to long-term the group has excellent prospects for its portfolio of drugs that can treat HIV, cancer, epilepsy and hypotension.

Pre-tax profit before exceptionals was $295.4m (£208m) in the year to last December against $204.2m the year before. The shares fell 240p to 520p.

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Create Account you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy policy .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in